Back pain breakthrough? own cells injected into damaged discs

NCT ID NCT07168603

Recruiting now Disease control Sponsor: ASTEROGENE Biomedical Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether a person's own disc cells, grown in a lab and injected back into the damaged disc, can safely treat degenerative disc disease. Twelve adults with disc herniation and persistent back pain will receive one injection of these cells. Researchers will monitor for side effects and check for pain relief and disc healing over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: autologous nucleus pulposus cells (aNPC)
What this could lead to: If successful, this could point toward a regenerative treatment for degenerative disc disease, potentially reducing pain and improving function without surgery.
What could go wrong: This is a very early, small trial (12 people) focused on safety. The treatment may not work, and there are risks of inflammation or injection-related complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEGENERATIVE DISC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intervertebral disk degenerative disorder lumbar disk degenerative disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTERVERTEBRAL DISC DEGENERATION

Contacts and locations

Locations

Taipei Medical University Hospital Clinical Research Center
RECRUITING

Taipei, 110, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.